Putting the E (evidence) in a new Era for myeloma

Leuk Lymphoma. 2011 Mar;52(3):349-50. doi: 10.3109/10428194.2011.557170.

Authors

Jonathan L Kaufman¹, Sagar Lonial

Affiliation

¹ Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA. [email protected]

PMID: 21323515
DOI: 10.3109/10428194.2011.557170

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Clinical Trials, Phase III as Topic
Evidence-Based Practice / methods
Evidence-Based Practice / trends*
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / mortality
Multiple Myeloma / mortality
Multiple Myeloma / therapy*
Randomized Controlled Trials as Topic
Recurrence
Rituximab
Survival Analysis

Substances

Antibodies, Monoclonal, Murine-Derived
Rituximab